Alzecure Q4: Well-positioned pipeline
Research Update
2024-02-28
09:45
Redeye reviews the case of Alzecure after the Q4 report, which offered no surprises, and continues to see an interesting neurology platform case with an exciting future. We adjust our base case somwhat due to external factors but reiterate our fundamental view.
FT
Fredrik Thor
Disclosures and disclaimers